The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation
| dc.contributor.author | Bermúdez, Valmore | |
| dc.contributor.author | Rojas-Quintero, Joselyn | |
| dc.contributor.author | Velasco, Manuel | |
| dc.date.accessioned | 2018-07-19T21:10:40Z | |
| dc.date.available | 2018-07-19T21:10:40Z | |
| dc.date.issued | 2017-12 | |
| dc.description.abstract | espite the monumental efforts directed into studying and describing the pathways, factors, genetic predisposition, and target-specific pharmacotherapy to atherosclerosis, ischemic heart disease, thrombotic cerebrovascular disease and peripheral artery disease are still responsible for 50% of all the deaths occurring in the developed world. The quest for a clear pathophysiology into atherosclerosis began with von Rokitansky’s incrustation theory, which evolved into the crucial role of platelets and thrombogenesis during acute coronary syndromes (1). Next, came the irritation theory postulated by Virchow, which detailed the presence of leukocytes in atherosclerotic plaques, suggesting the presence of chronic inflammation and progressive vessel deformation (1). By 1904, the term atherosclerosis was coined by Felix Jacob Marchand and 9 years later Nikolai Anichkov published that cholesterol alone can induce the vascular changes associated with atherosclerosis (1). The impeccable work performed by Anichkov and his team, paved the way to the current understanding and clinical logic used in current cardiovascular medicine (the lipid hypothesis), which for the longest period focused mainly in plasma lipids as sole culprits for atherogenesis. Genetic connection between cholesterol and heart disease came in 1939, when Müller described families with severe hypercholesterolemia and early onset cardiac disease and death (2). The recognition of hereditary hyperlipidemias and their characteristics, cemented the role on cholesterol in cardiovascular risk, along with the findings from the epidemiological mammoth, the Framingham Heart Study (3). At some point, the lipid hypothesis was “universally recognized as a law” [2002] (4), and as such, it dominated pharmacotherapy development in cardiovascular medicine. | spa |
| dc.identifier.issn | 20776624 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12442/2191 | |
| dc.language.iso | eng | eng |
| dc.publisher | AME Publishing Company | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.license | Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional | spa |
| dc.source | Journal Of Thoracic Disease | eng |
| dc.source | Vol. 10, No.1 (2018) | spa |
| dc.source.uri | http://jtd.amegroups.com/article/view/17942/14650 | eng |
| dc.subject | Mighty cholesterol | eng |
| dc.subject | Atherosclerosis | eng |
| dc.subject | Ischemic heart disease | eng |
| dc.subject | Thrombotic cerebrovascular disease | eng |
| dc.subject | Peripheral artery | eng |
| dc.title | The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation | eng |
| dc.type | article | eng |
| dcterms.references | Capron L. Pathogenesis of atherosclerosis: an update on the three main theories. Ann Cardiol Angeiol (Paris) 1989;38:631-4. | eng |
| dcterms.references | Müller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939;64:675-700. | eng |
| dcterms.references | Wilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980;46:649-54. | eng |
| dcterms.references | Thompson GR, Packard CJ, Stone NJ. Goals of statin therapy: three viewpoints. Curr Atheroscler Rep 2002;4:26-33. | eng |
| dcterms.references | Bertrand MJ, Tardif JC. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opin Emerg Drugs 2017;22:1-26. | eng |
| dcterms.references | DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol 2015;7:404-9. | eng |
| dcterms.references | Esselstyn CB. A plant-based diet and coronary artery disease: a mandate for effective therapy. J Geriatr Cardiol 2017;14:317-20. | eng |
| dcterms.references | Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80. | eng |
| dcterms.references | Nakaya K, Ikewaki K. Microbiota and HDL metabolism. Curr Opin Lipidol 2018;29:18-23. | eng |
| dcterms.references | Govea-Alonso DO, Beltrán-López J, Salazar-González JA, et al. Progress and future opportunities in the development of vaccines against atherosclerosis. Expert Rev Vaccines 2017;16:337-50. | eng |
| dcterms.references | Matsuura E, Atzeni F, Sarzi-Puttini P, et al. Is atherosclerosis an autoimmune disease? BMC Med 2014;12:47. | eng |
| dcterms.references | Vecchione C, Gentile MT, Aretini A, et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia 2007;50:874-80. | eng |
| dcterms.references | Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26. | eng |
| dcterms.references | Zhou X, Paulsson G, Stemme S, et al. Hypercholesterolemia is associated with a T helper (Th) 1/ Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998;101:1717-25. | eng |
| dcterms.references | Rojas J. Inflammasomes – Fighting the enemy from within. Avan Biomed 2012;1:18-29. | eng |
| dcterms.references | Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010;3:cm1. | eng |
| dcterms.references | Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial. Lancet 2017. [Epub ahead of print]. | eng |
| dcterms.references | Borovac JA, D’Amario D, Niccoli G . Neoatherosclerosis and late thrombosis after percutaneous coronary intervention: translational cardiology and comparative medicine from bench to bedside. Yale J Biol Med 2017;90:463-70. | eng |
| dcterms.references | Salazar J, Luzardo E, Mejías JC, et al. Epicardial Fat: physiological, pathological and therapeutic implications. Cardiol Res Pract 2016;2016:1291537. | eng |
| dcterms.references | Bermúdez V, Rojas J, Salazar J, et al. Sensitivity and Specificity Improvement in Abdominal Obesity Diagnosis Using Cluster Analysis during Waist Circumference Cut- Off Point Selection. J Diabetes Res 2015;2015:750265. | eng |
| dcterms.references | Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University- Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013;111:1394-400. | eng |
| dcterms.references | Chyu KY, Dimayuga PC, Shah PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines 2017;5:39-47. | eng |
| dcterms.references | Tourani M, Karkhah A, Najafi A. Development of an epitope-based vaccine inhibiting immune cells rolling and migration against atherosclerosis using in silico approaches. Comput Biol Chem 2017;70:156-63. | eng |
| dcterms.references | Mao D, Kai G, Gaofu Q, et al. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine 2006;24:4942-50. | eng |
Archivos
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 368 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: